Comparative Pharmacology
Head-to-head clinical analysis: PALBOCICLIB versus RIBOCICLIB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PALBOCICLIB versus RIBOCICLIB.
PALBOCICLIB vs RIBOCICLIB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclin-dependent kinase (CDK) 4 and 6 inhibitor; blocks phosphorylation of retinoblastoma protein, preventing cell cycle progression from G1 to S phase.
Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor. Selectively inhibits CDK4 and CDK6, leading to reduced phosphorylation of retinoblastoma protein, G1-to-S phase cell cycle arrest, and decreased proliferation of estrogen receptor-positive breast cancer cells.
125 mg orally once daily for 21 days, followed by 7 days off treatment; taken with food in combination with an aromatase inhibitor or fulvestrant.
600 mg orally once daily for 21 consecutive days followed by 7 days off treatment, in combination with an aromatase inhibitor or fulvestrant.
None Documented
None Documented
Clinical Note
moderatePalbociclib + Deslanoside
"Palbociclib may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderatePalbociclib + Acetyldigitoxin
"Palbociclib may decrease the cardiotoxic activities of Acetyldigitoxin."
Clinical Note
moderatePalbociclib + Ouabain
"Palbociclib may decrease the cardiotoxic activities of Ouabain."
Clinical Note
moderateRibociclib + Gatifloxacin
"The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Gatifloxacin."
Terminal elimination half-life of 24-29 hours, supporting once-daily dosing; steady-state reached within 8 days.
Terminal elimination half-life is 32.0 hours (range 29.2–40.4 hours), supporting once-daily dosing.
Primarily hepatic metabolism (CYP3A4) with 74% fecal excretion (17% as unchanged drug) and 18% renal excretion (1.5% unchanged).
Primarily hepatic metabolism (CYP3A4) with fecal excretion as major route (69% of dose as metabolites, 23% unchanged in feces); renal excretion accounts for approximately 12% (primarily as metabolites, <1% unchanged).
Category D/X
Category C
CDK4/6 Inhibitor
CDK4/6 Inhibitor